Asunaprevir is a potent HCV NS3 protease inhibitor (IC50 = 0.2-3.5 nM). Asunaprevir can be used to control CRIPSR-Cas9 gene editing via the small molecule-assisted shut-off (SMASh) technique, which involves fusion of Cas9 to a peptide comprising a protease domain and a degron tag. Asuprenavir blocks the protease-mediated removal of the degron tag leading to degradation of Cas9 through proteasome and autophagolysosome pathways. It can also be used as a resversible switch to control CAR (chimeric antigen receptor)-T cells, where the CAR has been modified by insertion of a hepatitis C virus nonstructural protein 3 protease (HCV-NS3) between the scFv and the hinge domains. Also inhibits SARS-CoV-2 Mpro activity (IC50 = 15-48.4 μM).
Caractéristiques techniques
| Marque | Tocris Bioscience |
|---|
| Réf. B-LABO | BL-RE-151102 |
|---|
| Réf. fabricant | 18737856 |
|---|
| Nom chimique ou matériau | 1-[[N-tert-Butoxycarbonyl-L-tert-leucyl-trans-4-[(7-chloro-4-methoxyisoquinolin-1-yl)oxy]-L-prolyl]amino]-N-(cyclopropylsulfonyl)-(1 R,2 S)-2-vinylcyclopropane-1-carboxamide |
|---|
| CAS | 630420-16-5 |
|---|
| Quantité | 50 mg |
|---|
| Cible | CRISPR Reagents |
|---|
| Formule moléculaire | C<sub>35</sub>H<sub>46</sub>ClN<sub>5</sub>O<sub>9</sub>S |
|---|
| Pureté | 0.98 |
|---|
Une question, une configuration particulière ?
Contactez-nous pour un devis.
